Lynparza (olaparib) — Medica
Breast cancer – recurrent or metastatic disease
Initial criteria
- age ≥ 18 years
- recurrent or metastatic disease
- ONE of the following: BRCA mutation-positive breast cancer OR germline PALB2 mutation-positive breast cancer
Approval duration
1 year